{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:25:21Z","timestamp":1783297521203,"version":"3.54.6"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"ministry of higher education and scientific research jordan","award":["2018126"],"award-info":[{"award-number":["2018126"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s10072-021-05682-5","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T13:05:40Z","timestamp":1635253540000},"page":"2621-2630","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Significance of serum VIP and PACAP in multiple sclerosis: an exploratory case\u2013control study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9857-4966","authenticated-orcid":false,"given":"Maha S.","family":"Al-Keilani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basima A.","family":"Almomani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour A.","family":"Al-Sawalha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majdi","family":"Al Qawasmeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saied A.","family":"Jaradat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"key":"5682_CR1","doi-asserted-by":"publisher","unstructured":"Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA et al (2020) Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS. Mult Scler 26(14):1816\u20131821. https:\/\/doi.org\/10.1177\/1352458520970841","DOI":"10.1177\/1352458520970841"},{"key":"5682_CR2","doi-asserted-by":"publisher","unstructured":"Baecher-Allan C, Kaskow BJ, Weiner HL (2018) Multiple sclerosis: mechanisms and immunotherapy. Neuron 97(4):742\u2013768. https:\/\/doi.org\/10.1016\/j.neuron.2018.01.021","DOI":"10.1016\/j.neuron.2018.01.021"},{"key":"5682_CR3","doi-asserted-by":"publisher","unstructured":"Comi G, Bar-Or A, Lassmann H, Uccelli A, Hartung HP, Montalban X et al (2021) Role of B cells in multiple sclerosis and related disorders. Ann Neurol 89(1):13\u201323. https:\/\/doi.org\/10.1002\/ana.25927","DOI":"10.1002\/ana.25927"},{"key":"5682_CR4","doi-asserted-by":"publisher","unstructured":"Kerschensteiner M, Meinl E, Hohlfeld R (2009) Neuro-immune crosstalk in CNS diseases. Neuroscience 158(3):1122\u20131132. https:\/\/doi.org\/10.1016\/j.neuroscience.2008.09.009","DOI":"10.1016\/j.neuroscience.2008.09.009"},{"key":"5682_CR5","doi-asserted-by":"publisher","unstructured":"Lassmann H, Br\u00fcck W, Lucchinetti C (2001) Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 7(3):115\u2013121. https:\/\/doi.org\/10.1016\/s1471-4914(00)01909-2","DOI":"10.1016\/s1471-4914(00)01909-2"},{"key":"5682_CR6","doi-asserted-by":"publisher","unstructured":"Baranowska-Bik A, Kochanowski J, Uchman D, Wolinska-Witort E, Kalisz M, Martynska L et al (2013) Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) in humans with multiple sclerosis. J Neuroimmunol 263(1\u20132):159\u2013161. https:\/\/doi.org\/10.1016\/j.jneuroim.2013.08.012","DOI":"10.1016\/j.jneuroim.2013.08.012"},{"key":"5682_CR7","doi-asserted-by":"publisher","unstructured":"Schwartz M, Deczkowska A (2016) Neurological disease as a failure of brain\u2013immune crosstalk: the multiple faces of neuroinflammation. Trends Immunol 37(10):668\u2013679. https:\/\/doi.org\/10.1016\/j.it.2016.08.001","DOI":"10.1016\/j.it.2016.08.001"},{"key":"5682_CR8","doi-asserted-by":"publisher","unstructured":"Wrona D (2006) Neural\u2013immune interactions: an integrative view of the bidirectional relationship between the brain and immune systems. J Neuroimmunol 172(1\u20132):38\u201358. https:\/\/doi.org\/10.1016\/j.jneuroim.2005.10.017","DOI":"10.1016\/j.jneuroim.2005.10.017"},{"key":"5682_CR9","doi-asserted-by":"publisher","unstructured":"Carniglia L, Ram\u00edrez D, Durand D, Saba J, Turati J, Caruso C et al (2017) Neuropeptides and microglial activation in inflammation, pain, and neurodegenerative diseases. Mediators Inflamm 2017:5048616. https:\/\/doi.org\/10.1155\/2017\/5048616","DOI":"10.1155\/2017\/5048616"},{"key":"5682_CR10","doi-asserted-by":"publisher","unstructured":"Souza-Moreira L, Campos-Salinas J, Caro M, Gonzalez-Rey E (2011) Neuropeptides as pleiotropic modulators of the immune response. Neuroendocrinology 94(2):89\u2013100. https:\/\/doi.org\/10.1159\/000328636","DOI":"10.1159\/000328636"},{"key":"5682_CR11","doi-asserted-by":"publisher","unstructured":"Tan Y-V, Abad C, Wang Y, Lopez R, Waschek J (2015) VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1\/Th17 and reduced Th2\/Treg responses. Brain Behav Immun 44:167\u2013175. https:\/\/doi.org\/10.1016\/j.bbi.2014.09.020","DOI":"10.1016\/j.bbi.2014.09.020"},{"key":"5682_CR12","doi-asserted-by":"publisher","unstructured":"Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Martin J, Pozo D, Ganea D et al (2006) Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. Am J Pathol 168(4):1179\u20131188. https:\/\/doi.org\/10.2353\/ajpath.2006.051081","DOI":"10.2353\/ajpath.2006.051081"},{"key":"5682_CR13","doi-asserted-by":"publisher","unstructured":"Kato H, Ito A, Kawanokuchi J, Jin S, Mizuno T, Ojika K et al (2004) Pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presenting cells. Mult Scler 10(6):651\u2013659. https:\/\/doi.org\/10.1191\/1352458504ms1096oa","DOI":"10.1191\/1352458504ms1096oa"},{"key":"5682_CR14","unstructured":"Kochanowski J, Uchman D, Litwiniuk A, Kalisz M, Wolinska-Witort E, Martynska L, et al (2015) Assessment of plasma brain-derived neurotrophic factor (BDNF), activity-dependent neurotrophin protein (ADNP) and vasoactive intestinal peptide (VIP) concentrations in treatment-naive humans with multiple sclerosis. Neuro Endocrinol Lett 36(2)"},{"key":"5682_CR15","doi-asserted-by":"publisher","unstructured":"Sun W, Hong J, Zang YC, Liu X, Zhang JZ (2006) Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis. Int Immunol 18(12):1691\u20131700. https:\/\/doi.org\/10.1093\/intimm\/dxl103","DOI":"10.1093\/intimm\/dxl103"},{"key":"5682_CR16","doi-asserted-by":"publisher","unstructured":"Mart\u00ednez C, Ortiz AM, Juarranz Y, Lamana A, Seoane IV, Leceta J, et al (2014) Serum levels of vasoactive intestinal peptide as a prognostic marker in early arthritis. Plos One 9(1):e85248. https:\/\/doi.org\/10.1371\/journal.pone.0085248","DOI":"10.1371\/journal.pone.0085248"},{"key":"5682_CR17","doi-asserted-by":"publisher","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"5682_CR18","doi-asserted-by":"publisher","unstructured":"Goldman MD, Motl RW, Rudick RA (2010) Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. Neurol Disord 3(4):229\u2013239. https:\/\/doi.org\/10.1177\/1756285610374117","DOI":"10.1177\/1756285610374117"},{"key":"5682_CR19","doi-asserted-by":"publisher","unstructured":"Sevim S (2016) Relapses in multiple sclerosis: definition, pathophysiology, features, imitators, and treatment. Turk Noroloji Dergisi 22(3). https:\/\/doi.org\/10.4274\/TND.75318","DOI":"10.4274\/TND.75318"},{"key":"5682_CR20","doi-asserted-by":"publisher","unstructured":"Lublin FD, Reingold SC, Cohen JA, Cutter GR, S\u00f8rensen PS, Thompson AJ et al (2014) Defining the clinical course of multiple sclerosis,\u201d The 2013 revisions. Neurology 83(3):278\u2013286. https:\/\/doi.org\/10.1212\/WNL.0000000000000560","DOI":"10.1212\/WNL.0000000000000560"},{"key":"5682_CR21","doi-asserted-by":"publisher","unstructured":"Unal I (2017) Defining an optimal cut-point value in ROC analysis: an alternative approach. Comput Math Methods Med 2017:3762651. https:\/\/doi.org\/10.1155\/2017\/3762651","DOI":"10.1155\/2017\/3762651"},{"key":"5682_CR22","doi-asserted-by":"publisher","unstructured":"Waschek JA (2013) VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair. Br J Pharmacol 169(3):512\u2013523. https:\/\/doi.org\/10.1111\/bph.12181","DOI":"10.1111\/bph.12181"},{"key":"5682_CR23","doi-asserted-by":"publisher","unstructured":"Bosca I, Coret F, Valero C, Pascual AM, Magraner MJ, Landete L, Casanova B (2008) Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon. Mult Scler 14(5):636\u2013639. https:\/\/doi.org\/10.1177\/1352458507086666","DOI":"10.1177\/1352458507086666"},{"key":"5682_CR24","doi-asserted-by":"publisher","unstructured":"Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y (2009) Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 73(20):1616\u20131623. https:\/\/doi.org\/10.1212\/WNL.0b013e3181c1e44f","DOI":"10.1212\/WNL.0b013e3181c1e44f"},{"key":"5682_CR25","doi-asserted-by":"publisher","unstructured":"Andersen O, Fahrenkrug J, Wikkels\u00f8 C, Johansson BB (1984) VIP in cerebrospinal fluid of patients with multiple sclerosis. Acta Neurol Scand 5(2):435\u2013437. https:\/\/doi.org\/10.1111\/j.1600-0404.1984.tb00830.x","DOI":"10.1111\/j.1600-0404.1984.tb00830.x"},{"key":"5682_CR26","doi-asserted-by":"publisher","unstructured":"Abad C, Jayaram B, Becquet L, Wang Y, O\u2019Dorisio MS, Waschek JA, Tan YV (2016) VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage. J Neuroinflammation 13(1):1\u201314. https:\/\/doi.org\/10.1186\/s12974-016-0626-3","DOI":"10.1186\/s12974-016-0626-3"},{"key":"5682_CR27","unstructured":"Caughey GH, Leidig F, Viro NF, Nadel JA (1988) Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. J Pharmacol Exp Ther 244(1):133\u2013137"},{"key":"5682_CR28","doi-asserted-by":"publisher","unstructured":"Rozniecki J, Hauser S, Stein M, Lincoln R, Theoharides TC (1995) Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. Ann Neurol 37(1):63\u201366. https:\/\/doi.org\/10.1002\/ana.410370112","DOI":"10.1002\/ana.410370112"},{"key":"5682_CR29","doi-asserted-by":"publisher","unstructured":"Ganea D, Hooper KM, Kong W (2015) The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases. Acta Physiol (Oxf) 213(2):442\u2013452. https:\/\/doi.org\/10.1111\/apha.12427","DOI":"10.1111\/apha.12427"},{"key":"5682_CR30","doi-asserted-by":"publisher","unstructured":"Reglodi D, Helyes Z, Nemeth J, Vass RA, Tamas A (2016) PACAP as a potential biomarker: alterations of PACAP levels in human physiological and pathological conditions. (11):815\u2013832. https:\/\/doi.org\/10.1007\/978-3-319-35135-3_48","DOI":"10.1007\/978-3-319-35135-3_48"},{"key":"5682_CR31","doi-asserted-by":"publisher","unstructured":"Mosca E, Rousseau J, Gulemetova R, Kinkead R, Wilson RJA (2015) The effects of sex and neonatal stress on pituitary adenylate cyclase\u2010activating peptide expression. Exp Physiol 100(2):203\u2013215. https:\/\/doi.org\/10.1113\/expphysiol.2014.082180","DOI":"10.1113\/expphysiol.2014.082180"},{"key":"5682_CR32","doi-asserted-by":"publisher","unstructured":"Laszlo E, Tamas J, Adam V, Bernadett C, Krisztina K, Peter D et al (2019) Protective effect of PACAP on ischemia\/reperfusion-induced kidney injury of male and female rats: gender differences. J Mol Neurosci 68(3):408\u2013419. https:\/\/doi.org\/10.1007\/s12031-018-1207-y","DOI":"10.1007\/s12031-018-1207-y"},{"key":"5682_CR33","doi-asserted-by":"publisher","unstructured":"Hou L, Wan D, Dong Z, Tang W, Han X, Li L, Yang F, Yu S (2016) Pituitary adenylate cyclase-activating polypeptide expression in peripheral blood mononuclear cells of migraineurs. Cell Biosci 6(1):1\u20136. https:\/\/doi.org\/10.1186\/s13578-016-0106-6","DOI":"10.1186\/s13578-016-0106-6"},{"key":"5682_CR34","doi-asserted-by":"publisher","unstructured":"Dow RC, Bennie J, Fink G (1994) Pituitary adenylate cyclase-activating peptide-38 (PACAP)-38 is released into hypophysial portal blood in the normal male and female rat. J Endocrinol 142(1):R1-R4. https:\/\/doi.org\/10.1677\/joe.0.142r001","DOI":"10.1677\/joe.0.142r001"},{"key":"5682_CR35","doi-asserted-by":"publisher","unstructured":"Winters SJ, King JC, Brees CK, Moore Jr JP (2014) Pituitary adenylate cyclase-activating polypeptide (PACAP) in fetal cord blood. Early Hum Dev 90(9):451\u2013453. https:\/\/doi.org\/10.1016\/j.earlhumdev.2014.06.001","DOI":"10.1016\/j.earlhumdev.2014.06.001"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05682-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-021-05682-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05682-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T07:12:58Z","timestamp":1647069178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-021-05682-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,26]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["5682"],"URL":"https:\/\/doi.org\/10.1007\/s10072-021-05682-5","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,26]]},"assertion":[{"value":"29 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Research and Ethics Committee at Jordan University of Science and Technology (registration number 17\/115\/2018).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All subjects signed a written informed consent in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}